Viyash Scientific Ltd Share Price
As on 13 June 2026 at 03:43 IST
Sequent Scientific Q1 FY26 Results:
Profit for the period increased 120.2% to ₹14.3 crores in Q1 FY26, from ₹6.5 crores in Q1 FY25. Total income for the quarter increased 13.3% year-on-year to ₹445.3 crores, from ₹392.9 crores.
About Viyash Scientific Ltd
Sequent Scientific Limited is an integrated pharmaceutical company focusing on animal health. It operates in the pharmaceutical sector, specifically in the veterinary pharmaceuticals segment. Founded in 1985, Sequent Scientific has been in business for decades, showcasing a strong and established presence in the industry. The headquarters of the company is in Mumbai, Maharashtra. It aims to be a leading integrated animal health company. Sequent Scientific's main products revolve around active pharmaceutical ingredients (APIs) and formulations for animal health. They cater to various therapeutic segments, including anti-infectives, anti-inflammatory, and anti-parasitic products. +
The Current prices are delayed, log in for live prices
LOGINOver 1 Month
10.64%
Over 6 Months
21.02%
Over 1 Year
24.69%
Over 3 Years
221.55%
Viyash Scientific Ltd Summary
Close ₹249.20
Open ₹252.90
High ₹255.40
Low ₹248.15
Volume 14,77,178
Net Turnover (in Cr) ₹37.05
52Wk High ₹277.35
52Wk Low ₹166
52Wk High / Low
166
277.35
Viyash Scientific Ltd Fundamentals
Key Financial Data
Market Cap (in Cr) ₹10,886.94
EPS (TTM) 2.40
Book Value (BV) 73
Div. Yield -
P/E (TTM) 143.30
Price/Book Value 3.42
Delivery % 50.40 %
Face Value 2
Key Ratios
PE Ratio 207.62
PB Ratio 2.87
EV to Sales 18.62
PEG Ratio 0.07
ROA 1.32
ROE 1.42
Debt-Equity 0.04
Net Profit Margin 8.86
Operating Profit Margin 19.45
Viyash Scientific Ltd Financials
Profit and Loss
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Total Revenue | 1,566.06 | 1,380.69 | 1,427.30 | 1,423.66 | 1,369.98 |
| Total Expenses | 1,516.77 | 1,417.94 | 1,500.16 | 1,370.73 | 1,224.53 |
| Profit Before Tax | 44.31 | -54.65 | -137.66 | 52.93 | 136.63 |
| Profit After Tax | 32.26 | -29.61 | -121.98 | 44.76 | 104.45 |
| Operating Profit After Depreciation | 110.03 | 10.83 | -37.35 | 68.70 | 169.84 |
Balance Sheet
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Fixed Assets | 586.59 | 596.80 | 609.21 | 567.26 | 537.66 |
| Total Non Current Assets | 729.02 | 729.45 | 749.33 | 667.79 | 678.97 |
| Total Current Assets | 872.92 | 810.94 | 779.79 | 783.18 | 713.59 |
| Total Assets | 1,601.95 | 1,540.38 | 1,529.12 | 1,450.97 | 1,392.56 |
| Total Shareholder's Fund | 704.47 | 656.56 | 698.78 | 692.10 | 727.65 |
Cash Flow
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Net Cash From Operating Activities | 83.36 | 30.60 | 16.81 | 30.60 | 114.75 |
| Net Cash Used In Investing Activities | -24.78 | -5.92 | -64.96 | -94.10 | 9.65 |
| Net Cash Used In Financing Activities | -60.73 | -1.44 | 32.23 | 67.26 | -138.75 |
Profit and Loss
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Total Revenue | 229.19 | 214.50 | 250.93 | 247.27 | 285.42 |
| Total Expenses | 202.26 | 208.48 | 260.67 | 231.58 | 241.97 |
| Profit Before Tax | 22.05 | -0.24 | -9.75 | 15.69 | 40.89 |
| Profit After Tax | 15.79 | 0.62 | -6.08 | 14.80 | 32.11 |
| Operating Profit After Depreciation | 30.89 | 10.38 | -7.23 | 17.30 | 46.13 |
Balance Sheet
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Fixed Assets | 46.40 | 42.52 | 56.72 | 66.90 | 65.78 |
| Total Non Current Assets | 1,114.68 | 1,090.82 | 1,047.75 | 978.37 | 983.56 |
| Total Current Assets | 107.53 | 96.78 | 75.02 | 145.86 | 118.56 |
| Total Assets | 1,222.20 | 1,187.60 | 1,122.77 | 1,124.23 | 1,102.12 |
| Total Shareholder's Fund | 1,142.65 | 1,087.23 | 1,058.36 | 1,041.09 | 1,029.51 |
Cash Flow
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Net Cash From Operating Activities | -1.13 | -26.94 | 37.75 | 9.36 | 2.34 |
| Net Cash Used In Investing Activities | -0.44 | 5.47 | -50.70 | -4.25 | 16.55 |
| Net Cash Used In Financing Activities | 0.67 | 22.32 | 0.24 | 7.25 | -21.33 |
| Particulars (in ₹ Cr.) | 2026-03 | 2025-12 | 2025-09 | 2025-06 | 2025-03 |
|---|---|---|---|---|---|
| Total Revenue | 919.96 | 858.41 | 850.30 | 441.42 | 401.70 |
| Total Expenses | 735.71 | 682.78 | 677.07 | 389.23 | 355.46 |
| Profit Before Tax | 125.24 | 73.07 | 102.37 | 25.52 | 16.31 |
| Profit After Tax | 66.38 | 48.52 | 72.90 | 17.57 | 10.38 |
| Operating Profit after Depreciation | 200.17 | 189.61 | 180.69 | 56.06 | 47.90 |
| Particulars (in ₹ Cr.) | 2026-03 | 2025-12 | 2025-09 | 2025-06 | 2025-03 |
|---|---|---|---|---|---|
| Total Revenue | 372.49 | 341.64 | 339.75 | 41.07 | 42.33 |
| Total Expenses | 309.80 | 271.30 | 287.70 | 43.11 | 45.15 |
| Profit Before Tax | 48.75 | 10.61 | 32.67 | 4.78 | 5.91 |
| Profit After Tax | 35.81 | -0.08 | 22.84 | 3.37 | 4.23 |
| Operating Profit after Depreciation | 82.44 | 86.63 | 69.37 | 9.44 | 9.45 |
Viyash Scientific Ltd Technicals
Support and Resistance
S3 S2 S1 Pivot R1 R2 R3
S1 246.43
S2 243.67
S3 239.18
Pivot 250.92
R1 253.68
R2 258.17
R3 260.93
Moving Average
20 SMA 247.42
50 SMA 223.03
100 SMA 213.53
200 SMA 209.06
Viyash Scientific Ltd Corporate Actions
Viyash Scientific Ltd
₹0.5/Share
Announcement Date 08 Sep 2021
Record Date 10 Sep 2021
Div Yield 25%
Viyash Scientific Ltd Peer Comparison
| Company | Price | Market Cap (in Cr) |
|---|---|---|
| Sun Pharmaceutical Industries Ltd | ₹1,794.30 | ₹4,30,512.67 |
| Divis Laboratories Ltd | ₹6,651.25 | ₹1,76,569.79 |
| Torrent Pharmaceuticals Ltd | ₹4,570 | ₹1,54,669.57 |
| Cipla Ltd | ₹1,383 | ₹1,11,725.01 |
| Zydus Lifesciences Ltd | ₹1,105.65 | ₹1,11,254.26 |
Viyash Scientific Ltd Top Mutal Funds Invested
| Fund Name | AUM |
|---|---|
| UTI-Healthcare Fund | 2.36% |
| Quant Small Cap Fund | 1.92% |
| Motilal Oswal Nifty Microcap 250 Index Fund | 0.49% |
| Bandhan BSE Healthcare Index Fund | 0.27% |
| Motilal Oswal BSE 1000 Index Fund | 0.02% |
Viyash Scientific Ltd News
Viyash Scientific to acquire Milan-based pet care company BioForLife
08 Jun 2026, 02:46 pm
Viyash Scientific rises after subsidiary inks Rs 188-crore deal to acquire Italy's BioForLife
Viyash Scientific rose 1.59% to Rs 259.20 after the company's wholly owned subsidiary, Alivira Animal Health, has inked a binding agreement to acquire a 100% stake in BioForLife Italia S.r.l. (BFL), a leading pet care company based in Milan, Italy.
08 Jun 2026, 02:05 pm
Viyash Scientific to discuss results
On 19 May 2026
13 May 2026, 10:25 am
Sequent Scientific to declare Quarterly Results
On 5 February 2026
22 Jan 2026, 10:21 am
Sequent Scientific allots 11,86,700 equity shares under ESOP
11 Nov 2025, 02:18 pm
Viyash Scientific Ltd Stock Analysis
- Annual revenue for Viyash Scientific Ltd increased by 6.85% to ₹229.19 crore in FY 2025 from ₹214.50 crore in FY 2024.
- Annual Net Profit for Viyash Scientific Ltd increased by 2439.23% to ₹15.79 crore in FY 2025 from ₹0.62 crore in FY 2024.
- Promoter Shareholding in Viyash Scientific Ltd decreased by 0.19% in the most recent quarter, from 61.43% in December 2025 to 61.31% in March 2026.
- Viyash Scientific Ltd delivered a 1-year return of 24.69% compared to the Nifty 50, which provided a return of -7.87% as of the last trading session.
- Viyash Scientific Ltd share price moved up by 2.37% from its previous close of INR ₹249.20. The latest Viyash Scientific Ltd share price is INR ₹255.10.
- Viyash Scientific Ltd share price today has been at a low of 252.35 and a high of 256.95. Over the past 52 weeks, the Viyash Scientific Ltd share price has seen a low of 166 and a high of 277.35.
About Viyash Scientific Ltd
Sequent Scientific Limited is an integrated pharmaceutical company focusing on animal health. They are engaged in the development and marketing of animal health active pharmaceutical ingredients and formulations. Sequent Scientific operates within the pharmaceutical sector, specifically in the veterinary pharmaceuticals segment. Founded in 1985, it has been in business for decades, showcasing a strong and established presence in the industry. The headquarters of Sequent Scientific is in Mumbai, Maharashtra, India.
The promoters of Sequent Scientific include CA Harbor Investments, with a 52.61% stake. Kamal K Sharma serves as the Chairman & Ind.Director of the company. The management team comprises experienced professionals from the pharmaceutical industry, guiding the company's strategic initiatives and operations. They are-
While Sequent Scientific is a significant player in the veterinary pharmaceutical industry, it may not be the number-one stock in the sector. However, the company holds a notable position and is recognised for its contributions and market presence.
Sequent Scientific Limited's registered office is in Mumbai, Maharashtra. Meanwhile, the office of the registrar is in Hyderabad, Telangana. Overall, Sequent Scientific is a well-established player in the veterinary pharmaceutical industry. With its strong promoter backing and comprehensive product portfolio, the company holds a significant market presence and continues to grow.
One of the core aspects of Sequent Scientific's vision is innovation. They continuously invest in research and development to create new products and improve existing ones. This focus on innovation allows them to address the evolving needs of the animal health industry. Their commitment to R&D ensures that they stay at the forefront of scientific advancements, enabling them to offer cutting-edge solutions to their customers.
Quality is another pillar of Sequent Scientific's vision. They strive to maintain the highest quality standards in all their products and services. This commitment to quality is reflected in their advanced manufacturing facilities, which are equipped with cutting-edge technology. These facilities strictly adhere to rigorous regulatory standards. By ensuring the highest levels of quality, Sequent Scientific aims to build trust with its customers. This dedication helps establish a strong reputation for excellence.
Sustainability is also a key component of Sequent Scientific's vision. They recognise the importance of protecting the environment and conserving resources for future generations. To achieve this, they implement eco-friendly practices in their operations. They also develop products that are safe for animals and the environment. Their sustainability efforts extend to their supply chain. Sequent Scientific also collaborates with partners who share their commitment to environmental stewardship.
Sequent Scientific's vision includes a strong focus on customer satisfaction. They aim to build enduring partnerships with their customers by understanding their needs and providing tailored solutions. This customer-centric approach helps them deliver value and build long-term relationships. They also offer comprehensive laboratory and technical support services to assist their customers in achieving optimal results.
The company places a high value on its employees and their development. They believe that a skilled and motivated workforce is essential to achieving their vision. As a result, they invest in training and development programs to enhance their employees' skills and knowledge. This focus on employee development helps create a positive work environment and drives the company's success.
Sequent Scientific's vision extends to its corporate social responsibility initiatives. They are committed to giving back to the communities in which they operate. Their CSR efforts include various programs and activities aimed at improving the well-being of people and animals. By engaging in these initiatives, Sequent Scientific aims to make a positive impact on society.
The company also emphasises the importance of ethical business practices. They are dedicated to conducting their operations with integrity and transparency. This commitment to ethics helps build trust with their stakeholders and ensures that they operate responsibly and sustainably.
Sequent Scientific's vision is to be a global leader in animal health. They aim to expand their presence in international markets and serve a diverse range of customers. Their global vision is supported by their strong network of partners and distributors, who help them reach new markets and deliver their products to customers around the world.
Overall, Sequent Scientific's vision is to be a leading integrated animal health company that provides high-quality and innovative solutions. They are committed to maintaining high standards of quality and compliance. Along with this, they also focus on building enduring partnerships with their customers. By continuously advancing science and technology, Sequent Scientific aims to make a positive impact on animal health worldwide, striving to establish themselves as a trusted leader in the industry.
The promoters of Sequent Scientific include CA Harbor Investments, with a 52.61% stake. Kamal K Sharma serves as the Chairman & Ind.Director of the company. The management team comprises experienced professionals from the pharmaceutical industry, guiding the company's strategic initiatives and operations. They are-
- Rajaram Narayanan
- Sharat Narasapur
- Gregory Andrews
- Neeraj Bharadwaj
While Sequent Scientific is a significant player in the veterinary pharmaceutical industry, it may not be the number-one stock in the sector. However, the company holds a notable position and is recognised for its contributions and market presence.
Sequent Scientific Limited's registered office is in Mumbai, Maharashtra. Meanwhile, the office of the registrar is in Hyderabad, Telangana. Overall, Sequent Scientific is a well-established player in the veterinary pharmaceutical industry. With its strong promoter backing and comprehensive product portfolio, the company holds a significant market presence and continues to grow.
The Vision of Sequent Scientific
Sequent Scientific aims to be a leading integrated animal health company. Their vision is built on a foundation of innovation and sustainability. They seek to provide high-quality veterinary solutions that improve the health and well-being of animals worldwide. The company is committed to maintaining high standards of quality and compliance in all its operations.One of the core aspects of Sequent Scientific's vision is innovation. They continuously invest in research and development to create new products and improve existing ones. This focus on innovation allows them to address the evolving needs of the animal health industry. Their commitment to R&D ensures that they stay at the forefront of scientific advancements, enabling them to offer cutting-edge solutions to their customers.
Quality is another pillar of Sequent Scientific's vision. They strive to maintain the highest quality standards in all their products and services. This commitment to quality is reflected in their advanced manufacturing facilities, which are equipped with cutting-edge technology. These facilities strictly adhere to rigorous regulatory standards. By ensuring the highest levels of quality, Sequent Scientific aims to build trust with its customers. This dedication helps establish a strong reputation for excellence.
Sustainability is also a key component of Sequent Scientific's vision. They recognise the importance of protecting the environment and conserving resources for future generations. To achieve this, they implement eco-friendly practices in their operations. They also develop products that are safe for animals and the environment. Their sustainability efforts extend to their supply chain. Sequent Scientific also collaborates with partners who share their commitment to environmental stewardship.
Sequent Scientific's vision includes a strong focus on customer satisfaction. They aim to build enduring partnerships with their customers by understanding their needs and providing tailored solutions. This customer-centric approach helps them deliver value and build long-term relationships. They also offer comprehensive laboratory and technical support services to assist their customers in achieving optimal results.
The company places a high value on its employees and their development. They believe that a skilled and motivated workforce is essential to achieving their vision. As a result, they invest in training and development programs to enhance their employees' skills and knowledge. This focus on employee development helps create a positive work environment and drives the company's success.
Sequent Scientific's vision extends to its corporate social responsibility initiatives. They are committed to giving back to the communities in which they operate. Their CSR efforts include various programs and activities aimed at improving the well-being of people and animals. By engaging in these initiatives, Sequent Scientific aims to make a positive impact on society.
The company also emphasises the importance of ethical business practices. They are dedicated to conducting their operations with integrity and transparency. This commitment to ethics helps build trust with their stakeholders and ensures that they operate responsibly and sustainably.
Sequent Scientific's vision is to be a global leader in animal health. They aim to expand their presence in international markets and serve a diverse range of customers. Their global vision is supported by their strong network of partners and distributors, who help them reach new markets and deliver their products to customers around the world.
Overall, Sequent Scientific's vision is to be a leading integrated animal health company that provides high-quality and innovative solutions. They are committed to maintaining high standards of quality and compliance. Along with this, they also focus on building enduring partnerships with their customers. By continuously advancing science and technology, Sequent Scientific aims to make a positive impact on animal health worldwide, striving to establish themselves as a trusted leader in the industry.
FAQ’s
What is the share price of Viyash Scientific Ltd today?
Viyash Scientific Ltd share price as on 12 Jun 2026 is ₹ 255.1
What is the Market Cap of Viyash Scientific Ltd?
The market cap of Viyash Scientific Ltd stock is ₹10,886.94 Cr.
What is the PE Ratio of Viyash Scientific Ltd?
The Price to Earnings (P/E) Ratio of Viyash Scientific Ltd is 207.62
What is the PB Ratio of Viyash Scientific Ltd?
The Price to Book (P/B) Ratio of Viyash Scientific Ltd is 2.87
What is the 52 week high of Viyash Scientific Ltd Share Price?
The 52 week high of Viyash Scientific Ltd share price stands at ₹277.35
What is the 52 week low of Viyash Scientific Ltd Share Price?
The 52 week low of Viyash Scientific Ltd share price stands at ₹166
How can I buy shares of Viyash Scientific Ltd?
Simply open a demat account with Torus Digital and place an order to buy shares of Viyash Scientific Ltd.
Open FREE
3-in-1 Account
for all your banking, trading and demat needs
Trade in stocks,
derivatives and F&O
